NCT04523571View on ClinicalTrials.gov

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

August 10, 2021

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

BNT162b1

Intramuscular injection

OTHER

Placebo

Intramuscular injection

Trial Locations (1)

210009

Jiangsu Provincial Center for Disease Control and Prevention, Taizhou

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
collaborator

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

INDUSTRY

lead

BioNTech SE

INDUSTRY